IntroductionRecent advances in mRNA and lipid nanoparticle (LNP) technology have allowed for the development of new vaccines and therapeutics, holding great promise for gene therapy. In 2018, patisiran (Onpattro) was approved as the first LNP-based therapeutic for the delivery of silencing (si)RNA for transthyretin-mediated amyloidosis1. The same platform has since been used to deliver mRNA to generate two of the most effective vaccines against COVID-19 (Comirnaty (Pfizer/BioNTech) and Spikevax ...